An Insight into Emergent Ways of Stemming the Tide of Glaucoma Scourge

Main Article Content

Timothy Olatunji Oladosu, MSc, RN http://orcid.org/0000-0001-7594-3933 Aderonke Bosede Awoseemo, PhD, RN

Abstract

Glaucoma, the silent thief of sight remains a beglaring eye condition leading to optic nerve damage due to elevated pressure within the eye. It is one of the major irreversible blinding eye conditions in the world, perhaps devastating as it is mostly without symptoms till considerable vision is lost. This comprehensive article acclaim the silentious nature of this ailment; highlights the distinctive features of glaucoma among other eye disorders; provides practical measures to optimize one’s eye health; shares experiences and feedbacks from people with glaucoma; and identifies promising prospects of glaucoma diagnosis and management. The information therein aims to create awareness about the course and scourge of glaucoma to readers, as well as call the attention of the eye health practitioners to the perceived challenges encountered by patients with glaucoma with the aim of improving consumer’s outcome and quality of life.

Keywords: Glaucoma, ocular disorders, blindness, diagnosis, management, advances, challenges, prospects, patient considerations

Article Details

How to Cite
OLADOSU, Timothy Olatunji; AWOSEEMO, Aderonke Bosede. An Insight into Emergent Ways of Stemming the Tide of Glaucoma Scourge. Medical Research Archives, [S.l.], v. 11, n. 10, oct. 2023. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/4519>. Date accessed: 16 july 2024. doi: https://doi.org/10.18103/mra.v11i10.4519.
Section
Research Articles

References

1. World Glaucoma Association. World Glaucoma Week, March 12-18, 2023. https://www.worldglaucomaweek.org/what-is-glaucoma/
2. Khurana AK. Comprehensive Ophthalmology. 4th ed. New Age International Limited Publishers; 2007. http://www.grsmu.by/files/file/university/cafedry/oftalmologii/files/fiy/1.pdf
3. What’s the difference between Glaucoma and Cataracts? https://www.healthline.com/health/glaucoma-vs-cataracts
4. Owsley C, Rhodes LA, McGwin G Jr, et al. Eye Care Quality and Accessibility Improvement in the Community (EQUALITY) for adults at risk for glaucoma: study rationale and design. Int J Equity Health. 2015;14:135. Published 2015 Nov 18. doi:10.1186/s12939-015-0213-8
5. Oladosu TO, Faronbi JO. Qualitative Survey of Self-care practices of patients with glaucoma in Osun State, Nigeria. Nigerian Journal of Nursing. 2021;2(1):79-94
6. National Eye Institute. Facts about Glaucoma: National Eye Institute Education Program. https://www.nei.nih.gov/learn-about-eye- health/outreachresources/outreach-materials/facts-about-glaucoma
7. Liu Y. The Genetics of Glaucoma: Glaucoma Research Foundation. 2022. https://glaucoma.org/the-genetics-of-glaucoma/
8. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901-1911. doi:10.1001/jama.2014.3192
9. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 2: Classification and terminology. British Journal of Ophthalmology 2017;101:73-127. doi:10.1136/bjophthalmol-2016-EGSguideline.002
10. Kaur D, Gupta A, Singh G. Perspectives on Quality of Life in Glaucoma. J Curr Glaucoma Pract. 2012;6(1):9-12. doi:10.5005/jp-journals-10008-1101
11. Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008;53 Suppl1:S57-S68. doi:10.1016/j.survophthal.2008.08.002
12. Friedman DS, Hahn SR, Gelb L, et al. Doctor-patient communication, health-related beliefs, and adherence in glaucoma results from the Glaucoma Adherence and Persistency Study. Ophthalmology. 2008;115(8):1320-1327.e13273. doi:10.1016/j.ophtha.2007.11.023
13. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48(11):5052-5057. doi:10.1167/iovs.07-0290
14. Quigley HA, Friedman DS, Hahn SR. Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the Glaucoma Adherence and Persistency Study. Ophthalmology. 2007;114(9):1599-1606. doi:10.1016/j.ophtha.2007.03.042
15. Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care. 2002;8(10 Suppl):S262-S270. https://pubmed.ncbi.nlm.nih.gov/12188169/
16. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8(10 Suppl):S255-S261. https://pubmed.ncbi.nlm.nih.gov/12188168/
17. Coleman AL. Advances in glaucoma treatment and management: surgery. Invest Ophthalmol Vis Sci. 2012;53(5):2491-2494. Published 2012 May 4. doi:10.1167/iovs.12-9483l https://iovs.arvojournals.org/article.aspx?articleid=2126996
18. Gedde SJ, Schiffman JC, Feuer WJ, et al. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012;153(5):789-803.e2. doi:10.1016/j.ajo.2011.10.026. https://pubmed.ncbi.nlm.nih.gov/22245458/
19. Kersey T, Clement CI, Bloom P, Cordeiro MF. New trends in glaucoma risk, diagnosis & management. Indian J Med Res. 2013;137(4):659-668. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724246/
20. Dong ZM, Wollstein G, Schuman JS. Clinical Utility of Optical Coherence Tomography in Glaucoma. Invest Ophthalmol Vis Sci. 2016;57(9):OCT556-OCT567. doi:10.1167/iovs.16-19933. https://iovs.arvojournals.org/article.aspx?articleid=2545658
21. Tan O, Li G, Lu AT, Varma R, Huang D; Advanced Imaging for Glaucoma Study Group. Mapping of macular substructures with optical coherence tomography for glaucoma diagnosis. Ophthalmology. 2008;115(6):949-956. doi:10.1016/j.ophtha.2007.08.011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692598/
22. Tan O, Chopra V, Lu AT, et al. Detection of macular ganglion cell loss in glaucoma by Fourier-domain optical coherence tomography. Ophthalmology. 2009;116(12):2305-2314.e142. doi:10.1016/j.ophtha.2009.05.025 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2787911/
23. Spaide RF, Fujimoto JG, Waheed NK. Optical Coherence Tomography Angiography. Retina. 2015;35(11):2161-2162. doi:10.1097/IAE.0000000000000881. https://pubmed.ncbi.nlm.nih.gov/26502006/
24. Kumar RS, Anegondi N, Chandapura RS, et al. Discriminant Function of Optical Coherence Tomography Angiography to Determine Disease Severity in Glaucoma. Invest Ophthalmol Vis Sci. 2016;57(14):6079-6088. doi:10.1167/iovs.16-19984. https://pubmed.ncbi.nlm.nih.gov/27820876/
25. Yarmohammadi A, Zangwill LM, Diniz-Filho A, et al. Optical Coherence Tomography Angiography Vessel Density in Healthy, Glaucoma Suspect, and Glaucoma Eyes. Invest Ophthalmol Vis Sci. 2016;57(9):OCT451-OCT459. doi:10.1167/iovs.15-18944 https://pubmed.ncbi.nlm.nih.gov/27409505/
26. AlSalem M, Yang A, Noorani S, Deng T, Li X, Adams-Huet B, et al. Effectiveness of optical coherence tomography angiography (OCT-A) in staging glaucoma. Journal of the Royal Medical Services. 2022;29(2):1-15. Doi:10.12816/0061165. http://rmsjournal.org/Articles/637954687943319488.pdf
27. Kooner K, Rehman M, Suresh S, Buchanan E, Albdour M, Zuberi H. The Role of Optical Coherence Tomography Angiography in Glaucoma [Internet]. Optical Coherence Tomography - Developments and Innovations in Ophthalmology [Working Title]. IntechOpen; 2023. Available from: http://dx.doi.org/10.5772/intechopen.110272
28. Broadway DC. Visual field testing for glaucoma - a practical guide. Community Eye Health. 2012;25(79-80):66-70 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3588129/
29. Young TL. Glaucoma Research Foundation; Genetic Testing in Glaucoma. https://glaucoma.org/genetic-testing-in-glaucoma/
30. Wade M. Glaucoma Genetics: When is Testing Warranted? EyeNet Magazine’s Clinical Update, June 2023. https://www.aao.org/eyenet/article/glaucomagenetics-when-is-testing- warranted
31. Mohan N, Chakrabarti A, Nazm N, Mehta R, Edward DP. Newer advances in medical management of glaucoma. Indian J Ophthalmol. 2022;70(6):1920-1930. doi:10.4103/ijo.IJO_2239_21 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359258/
32. Vishwaraj CR, Kavitha S, Venkatesh R, Shukla AG, Chandran P, Tripathi S. Neuroprotection in glaucoma. Indian J Ophthalmol. 2022;70(2):380-385. doi:10.4103/ijo.IJO_1158_21 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023948/
33. Cegielska O, Sajkiewicz P. Targeted Drug Delivery Systems for the Treatment of Glaucoma: Most Advanced Systems Review. Polymers (Basel). 2019;11(11):1742. Published 2019 Oct 24. doi:10.3390/polym11111742 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918324/
34. Quigley HA. Glaucoma. Lancet. 2011;377(9774):1367-1377. doi:10.1016/S0140-6736(10)61423-7. https://pubmed.ncbi.nlm.nih.gov/21453963/